AMLX (Amylyx Pharmaceuticals, Inc.) Stock Financials & Earnings

AMLXAmylyx Pharmaceuticals, Inc.

Mkt Cap$1B

Healthcare·Biotechnology·🇺🇸 United States·NASDAQ

Revenue (TTM)$0

Net Income (TTM)-$145M

EPS (TTM)-$1.53

Free Cash Flow (TTM)-$123M

Gross Margin—

Op. Margin—

Net Margin—

FCF Margin—

P/S Ratio (TTM)—

P/E Ratio (TTM)—

YoY Rev Growth-100.0%

Employees—

Earnings Reports

Next: Q1 2026 · Apr 1

Revenue & Profitability

Quarter	Revenue	Gross Profit	Op. Income
Q1 23	$71M	$66M	-$2M
Q2 23	$98M	$93M	$20M
Q3 23	$103M	$97M	$19M
Q4 23	$108M	$99M	$2M
Q1 24	$89M	-$28M	-$122M
Q2 24	-$1M	-$9M	-$53M
Q3 24	$416K	-$393K	-$76M
Q4 24	-$665K	-$665K	-$41M
Q1 25	$0	$0	-$38M
Q2 25	$0	-$141K	-$43M
Q3 25	$0	-$20M	-$36M
Q4 25	$0	$20M	-$37M

Valuation

Operating Cash Flow

Capital Expenditures

CapEx

OpEx vs Revenue Growth (YoY)

Stock-Based Compensation

OpEx Breakdown

Quarter	R&D	G&A	SG&A
Q1 23	$24M	$44M	—
Q2 23	$29M	—	$43M
Q3 23	$30M	—	$49M
Q4 23	$45M	—	$52M
Q1 24	$37M	—	$58M
Q2 24	$23M	—	$22M
Q3 24	$21M	—	$18M
Q4 24	$23M	—	$17M
Q1 25	$22M	—	$16M
Q2 25	$27M	—	$16M
Q3 25	$20M	—	$16M
Q4 25	$21M	—	$15M

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 23	$115M	$231M	$346M
Q2 23	$248M	$110M	$357M
Q3 23	$135M	$220M	$355M
Q4 23	$170M	$201M	$371M
Q1 24	$171M	$203M	$373M
Q2 24	$75M	$235M	$310M
Q3 24	$72M	$163M	$234M
Q4 24	$77M	$99M	$177M
Q1 25	$60M	$144M	$204M
Q2 25	$58M	$123M	$181M
Q3 25	$225M	$119M	$344M
Q4 25	$227M	$90M	$317M

Shares Outstanding

Revenue Per Employee

Revenue / Employee